SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current assets$723.50 MCurrent liabilities$347.38 MLiabilities$396.88 MAssets$1.43 BNon-current liabilities$49.51 MEquity$1.03 BGross equity(calculated)$1.03 BNon-current assets$704.61 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSAccounts receivable, netMarketable securitiesCash and cash equivalentsInventories, netPrepaid expenses and other current assetsIntangible assets, netGoodwillOther assetsDeferred income tax assets, netProperty and equipment, netRestricted cashAccrued product returns and rebatesAccounts payable and accrued liabilitiesOther current liabilitiesOperating lease liabilities, long-termOther liabilitiesContingent consideration, long-termAdditional paid-in capitalRetained earningsCommon stock, $0.001 par value; 130,000,000 shares authorized; 58,164,352 and 57,457,462 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated other comprehensive loss, net of taxCurrent assetsCurrent assets$723.50 MCurrent liabilitiesCurrent liabilities$347.38 MAccounts receivable, netAccounts receivable, net$211.66 MAccrued product returns and rebatesAccrued product returns and rebates$198.84 MLiabilitiesLiabilities$396.88 MAccounts payable and accrued liabilitiesAccounts payable and accrued liabilities$108.46 MMarketable securitiesMarketable securities$192.11 MAssetsAssets$1.43 BOther current liabilitiesOther current liabilities$40.08 MCash and cash equivalentsCash and cash equivalents$179.95 MInventories, netInventories, net$83.92 MOperating lease liabilities, long-termOperating lease liabilities, long-term$29.43 MNon-current liabilitiesNon-current liabilities$49.51 MEquityEquity$1.03 BPrepaid expenses and other current assetsPrepaid expenses and other current assets$55.85 MOther liabilitiesOther liabilities$19.87 MContingent consideration, long-termContingent consideration, long-term$206.00 KGross equity (calculated)Gross equity(calculated)$1.03 BIntangible assets, netIntangible assets, net$469.46 MNon-current assetsNon-current assets$704.61 MAdditional paid-in capitalAdditional paid-in capital$574.09 MGoodwillGoodwill$119.43 MOther assetsOther assets$55.02 MDeferred income tax assets, netDeferred income tax assets, net$49.06 MRetained earningsRetained earnings$457.21 MProperty and equipment, netProperty and equipment, net$10.20 MCommon stock, $0.001 par value; 130,000,000 shares authorized; 58,164,352 and 57,457,462 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$58.00 KRestricted cashRestricted cash$1.45 MAccumulated other comprehensive loss, net of taxAccumulated other comprehensive loss, net of tax−$138.00 K
Chart details

SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
1,428,109,000 US dollars
Current assets
723,496,000 US dollars
Non-current assets
704,613,000 US dollars
Liabilities
396,883,000 US dollars
Current liabilities
347,378,000 US dollars
Non-current liabilities
49,505,000 US dollars
Equity
1,031,226,000 US dollars
Accounts receivable, net
211,656,000 US dollars
Marketable securities
192,114,000 US dollars
Cash and cash equivalents
179,953,000 US dollars
Inventories, net
83,924,000 US dollars
Prepaid expenses and other current assets
55,849,000 US dollars
Intangible assets, net
469,459,000 US dollars
Goodwill
119,431,000 US dollars
Other assets
55,015,000 US dollars
Deferred income tax assets, net
49,061,000 US dollars
Property and equipment, net
10,197,000 US dollars
Restricted cash
1,450,000 US dollars
Accrued product returns and rebates
198,844,000 US dollars
Accounts payable and accrued liabilities
108,458,000 US dollars
Other current liabilities
40,076,000 US dollars
Contingent consideration, current portion
0 US dollars
Operating lease liabilities, long-term
29,427,000 US dollars
Other liabilities
19,872,000 US dollars
Contingent consideration, long-term
206,000 US dollars
Additional paid-in capital
574,094,000 US dollars
Retained earnings
457,212,000 US dollars
Common stock, $0.001 par value; 130,000,000 shares authorized; 58,164,352 and 57,457,462 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
58,000 US dollars
Accumulated other comprehensive loss, net of tax
negative 138,000 US dollars
Gross equity (calculated)
1,031,364,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!